RPRX | Royalty Pharma PLC

CUSIP: G7709Q104

2 Funds Holding

6.1M Total Shares

$340M Total Value

$61.92
Price

$35.8B

Market Cap

33.3

P/E Ratio

10.8

Forward P/E

$1.86

EPS (TTM)

1.52%

Dividend Yield

$837M

Cash

$9.0B

Total Debt

445M

Shares Out

$34.08

$62.45

52-Week Range

Fund / Manager Click to search	Shares	Value	% of Portfolio	Cost Basis	Est. Return
Patient Capital Management\|Samantha McLemore	3.6M	$202M	6.62%	$29.94	+106.79%
Dorsey Asset Management\|Pat Dorsey	2.5M	$138M	8.82%	$37.42	+65.46%

Quarter:

Fund / Manager Click to search	Action	Change	Shares After	Value	Price
2026-Q2
Patient Capital Management	SELL	-1.2%	3.6M	$202M	$52.41
Dorsey Asset Management	BUY	+7.9%	2.5M	$138M	$52.41
2026-Q1
Patient Capital Management	BUY	+9.3%	3.6M	$175M	$45.12
Dorsey Asset Management	BUY	+0.8%	2.3M	$109M	$45.12
2025-Q4
Patient Capital Management	BUY	+6.9%	3.3M	$129M	$38.43
Dorsey Asset Management	SELL	-3.9%	2.3M	$87M	$38.43
2025-Q3
Patient Capital Management	BUY	+4.3%	3.1M	$110M	$36.17
Dorsey Asset Management	BUY	NEW	2.4M	$83M	$36.17
2025-Q2
Patient Capital Management	BUY	+0.5%	3.0M	$108M	$32.82
2025-Q1
Patient Capital Management	BUY	+3.4%	3.0M	$93M	$32.25
2024-Q4
Patient Capital Management	BUY	+40.9%	2.9M	$73M	$26.43
2024-Q3
Patient Capital Management	BUY	+43.3%	2.0M	$58M	$27.78
2024-Q2
Patient Capital Management	BUY	+0.3%	1.4M	$38M	$27.70
2024-Q1
Patient Capital Management	BUY	+13.2%	1.4M	$43M	$29.43
2023-Q4
Patient Capital Management	BUY	NEW	1.3M	$35M	$27.35
2022-Q2
Berkshire Hathaway	SELL	EXIT	—	—	$40.77
2022-Q1
Berkshire Hathaway	SELL	-82.7%	1.5M	$58M	$39.14
2021-Q4
Berkshire Hathaway	SELL	-34.2%	8.6M	$345M	$38.55
2021-Q3
Berkshire Hathaway	BUY	NEW	13.1M	$475M	$38.73

No Insider Transactions

No Form 4 filings found for this stock in the last 2 years.